Status:
COMPLETED
Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Esophageal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective of this study is to find out the response rate of twice weekly paclitaxel and cisplatin and weekly HDFL in recurrent or metastatic esophageal carcinoma patients who need palliati...
Detailed Description
The primary objective of this study is to find out the response rate of twice weekly paclitaxel and cisplatin and weekly HDFL in recurrent or metastatic esophageal carcinoma patients who need palliati...
Eligibility Criteria
Inclusion
- Pathologically proven esophageal squamous cell or adenocarcinoma Recurrence or metastasis Measurable disease (\> 1 X 1 cm) by CXR, CT scan or MRI,Age \> 18, KPS \> 60% , Cre \< 1.5mg/dl, AST/ALT \< 3.5 X N, Bil \< 2.0mg/dl WBC \> 4,000/mm3, ANC \> 2,000/ mm3, Plt \> 100,000/mm3
Exclusion
- Prior chemo (except as radiosensitizers)Recurrent, treated esophageal lesion only (except \> 2 months)
Key Trial Info
Start Date :
January 1 2001
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00154700
Start Date
January 1 2001
End Date
July 1 2005
Last Update
December 20 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Oncology, National Taiwan University Hospital
Taipei, Taiwan, 100